New hope for tough breast cancer: experimental combo enters human testing
NCT ID NCT06351332
Summary
This study is testing a new drug called azenosertib, combined with two existing cancer drugs, for people with advanced triple-negative breast cancer that has spread. The main goals are to find a safe dose and see if the combination makes tumors shrink. About 78 participants will help researchers understand if this three-drug approach is effective and manageable.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.